US Pharma MarketingLatus Bio secures $97m in funding to boost gene therapy access
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups. The proceeds from the financing will fund Latus Bio’s operations through key clinical milestones. Latus Bio is scaling gene therapy for rare and common diseases. Credit: shisu_ka / Shutterstock.com. Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider patient groups. The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures.…
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies targeting wider patient groups.
Source: Pharmaceutical Technology